Cronos Group Inc.

NASDAQ:CRON

Drug Manufacturers - Specialty & Generic

Healthcare
$3.17 -0.56%

-$0.02 today

Market cap
$1.16B
Beta
1.25
P/E (TTM)
-488.3
EPS (TTM)
-$0.01
52W Low $1.84High $3.43

Volume 1.13M

Average 1.51M

CRON Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Cronos Group Inc.NASDAQ: CRON

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 385.31M shares rose 0.6% year over year, in line with the +0.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.7% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +0.6% toward the trailing-twelve-month pace of +0.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
385.31M+0.0% QoQ
Last fiscal yearDec 2025
385.31M+0.9% YoY
LTMMar 2026
385.31M+0.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.6%——
1 year+0.9%——
3-year CAGR+0.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
385.31M USD
Year-over-year change
+0.9%
4-year CAGR
+1.0%

Weighted Avg Shares vs competitors

How CRON compares with its peers on the latest reported figures

  • CRON's LTM Mar 2026 weighted avg shares of 385.31M shares is the highest of the 11 companies compared; the peer median is 44.64M shares.
  • Its year-over-year change of +0.8% is the 6th highest of 11, against a peer median of +2.8%.
  • Over three fiscal years its annual growth of +0.7% compares with a peer median of +4.1%.
CRON Competitors Peer median
Weighted Avg Shares for CRON and competitors
Company Period LTM YoY 3-year CAGR
CRONCronos Group Inc.LTM Mar 2026385.31M +0.8%+0.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026106.95M +29.6%+21.3%
PHATPhathom Pharmaceuticals, Inc.LTM Mar 202675.43M +13.3%+23.1%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
EMBCEmbecta Corp.LTM Mar 202658.4M +0.1%+0.7%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202646.16M -4.6%-1.3%
PCRXPacira BioSciences, Inc.LTM Mar 202643.11M -6.7%-0.7%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
COLLCollegium Pharmaceutical, Inc.LTM Mar 202631.79M -1.1%-2.1%
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 202627.33M +25.4%+15.0%
IRMDIRadimed CorporationLTM Mar 202612.74M +0.4%+0.4%
Peer median (excluding CRON) 44.64M+2.8%+4.1%

Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue64.56M86.75M87.24M117.62M149.15M
Cost of Revenue82.15M71.31M75.33M92.42M87.45M
Gross Profit(17.59M)15.44M11.91M25.2M61.7M
Gross Margin-27.3%17.8%13.7%21.4%41.4%
Research & Development21.84M13.13M5.84M4.23M4.45M
Selling, General & Admin121.68M100.73M80.93M76.82M63.76M
Operating Expenses274.38M126.86M96.71M101.73M79.54M
Depreciation & Amortization15.4M13.12M8.11M9.34M14.48M
EBITDA(150.13M)(91.27M)(71.8M)(50.21M)(3.36M)
EBITDA Margin-232.5%-105.2%-82.3%-42.7%-2.3%
Operating Income(291.97M)(111.43M)(84.8M)(76.53M)(17.84M)
Operating Margin-452.2%-128.4%-97.2%-65.1%-12.0%
Interest Income9.07M22.51M51.24M52.02M40.66M
Interest Expense27K13K000
Other Income / Expenses163.46M(9.58M)11.13M113.12M419.21K
Income Before Tax(128.51M)(121M)(73.67M)36.59M(17.42M)
Pre-Tax Margin-199.1%-139.5%-84.4%31.1%-11.7%
Income Tax Expense(431K)34.18M(3.23M)(3.44M)(14.44M)
Net Income(396.11M)(168.73M)(73.96M)41.08M(9.61M)
Net Margin-613.5%-194.5%-84.8%34.9%-6.4%
EPS (Basic)(1.07)(0.45)(0.19)0.11(0.03)
EPS (Diluted)(1.07)(0.45)(0.19)0.11(0.03)
Weighted Avg Shares370.39M376.96M403.4M382.06M385.31M
Weighted Avg Shares (Diluted)370.39M376.96M380.97M385.56M385.31M

Cronos Group Inc.

NASDAQ:CRON

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.